Metastatic Breast Cancer
Relevance: High
Strength of Science: High
15 May 2025
Study : Enhertu shows promising results for HER2-low and HER2-ultralow metastatic breast cancer
Most relevant for: People with HR-positive metastatic breast cancer
Recent study results show that a new targeted treatment works better than standard chemotherapy for people with metastatic hormone receptor-positive breast cancers with low or ultralow HER2 status. (Posted 5/15/25)
READ MORE ›
Relevance: Medium-High
Strength of Science: Medium-High
27 September 2024
Study : Use of cannabis for cancer symptom management
Most relevant for: People with cancer interested in using cannabis to help manage symptoms.
Among people with cancer, interest in the use of cannabis to manage cancer symptoms and treatment side effects is high. The world's leading professional organization of oncologists has published strategies to help adults with cancer and their healthcare providers have open, nonjudgmental discussions about the use of cannabis to manage cancer symptoms. (Posted 9/27/24)
Este artículo está disponible en español.
READ MORE ›
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
17 September 2024
Study : Combining two anti-HER2 drugs improves outcomes more effectively than one
Most relevant for: People with Her2-positive metastatic breast cancer
Combining two anti-HER2 drugs increased the time until cancer returned for people with locally advanced or metastatic HER2-positive breast cancer compared to people who received just one anti-HER2 drug. People whose breast cancer had metastasized to the brain also benefitted from the two combined drugs. (Posted 9/17/24)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium
Research Timeline: Post Approval
16 August 2024
Update : News from the FDA: Updates on breast cancer treatment
Most relevant for: People with BioZorb markers in breast tissue. People who will have a lumpectomy. People interested in cancer-related podcasts.
The FDA updates the risks of using BioZorb Markers and approves a new imaging drug for breast cancer. (Posted 8/16/24)
Este artículo está disponible en español.
READ MORE ›
Relevance: High
Research Timeline: Post Approval
7 August 2024
Topic : Acupressure for cancer symptom relief
Most relevant for: People diagnosed with cancer
Acupressure is a safe treatment that can be used to relieve some symptoms of cancer and side effects of treatment. Light pressure applied to key points on the body may help with fatigue, sleep, nausea and possibly other symptoms as well. (Posted 8/1/24)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
19 July 2024
Topic : The drug Enhertu is FDA-approved for any advanced or metastatic HER2-positive tumors
Most relevant for: People with advanced HER2-positive cancer
The FDA granted accelerated approval of Enhertu for people with any HER2-positive tumor that is metastatic or cannot be surgically removed. Eligible patients must have had previous treatment such as chemotherapy or hormone therapy. (Posted 7/19/24)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium-High
17 July 2024
Topic : Experts call for early palliative care for cancer patients
Most relevant for: Cancer patients
People with cancer need support and care not only at the end of life but from the time of diagnosis. At the 2024 American Society of Clinical Oncology (ASCO) annual meeting, the organization’s president urged cancer healthcare professionals to make palliative care central to cancer treatment. (Posted 7/17/24)
Este artículo está disponible en español.
READ MORE ›
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
15 March 2024
Study : Genetic testing among people with cancer can find mutations that may affect treatment and prevention
Most relevant for: People diagnosed with cancer who have not yet had genetic testing
Despite national guidelines recommending genetic testing, less than 10 percent of eligible patients had genetic testing within two years after their cancer diagnosis. Among those who had testing, 10-30 percent had an inherited mutation that could affect their medical care. (Posted 3/15/2024)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium
21 February 2024
Update : News from the FDA– new breast cancer treatment, thermography warning and implant screening updates
Most relevant for: People with HR-positive and HER2-negative metastatic breast cancer. People with silicone breast implants. People considering thermography screening
This XRAY review is a summary of FDA breast cancer updates from July to December 2023. This includes a new drug approval and two consumer updates. (Posted 2/21/24)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium-High
Research Timeline: Post Approval
9 February 2024
Update : New drug combination for the second treatment of some HR-positive advanced breast cancers
Most relevant for: People with hormone receptor (HR)-positive or HER2-negative breast cancer that has spread outside the breast tissue.
The FDA approved Truqap plus Faslodex for the treatment of metastatic hormone receptor-positive (HR-positive), HER2-negative breast cancer that returned or worsened after treatment with hormone therapy. The approval is for treating cancers in people whose tumors had a mutation in one of three genes. For people with one of these mutations, Truqap improved the time until their cancer came back or got worse. (Posted 2/9/24)
Este artículo está disponible en español.
READ MORE ›